[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $822.27, indicating a -0.22% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=c7a4d0d1e0e4a78e409315dd99691013188864acffeb069cbb82773d529bc534",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741815914,
      "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
      "id": 133184275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $822.27, indicating a -0.22% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=c7a4d0d1e0e4a78e409315dd99691013188864acffeb069cbb82773d529bc534"
    }
  },
  {
    "ts": null,
    "headline": "Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion",
    "summary": "Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.",
    "url": "https://finnhub.io/api/news?id=9d4ec59f6037fefdbdcd47a67f7600dc71ffa187ce9b258dd50d70a5e8a54a3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741810157,
      "headline": "Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion",
      "id": 133184276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.",
      "url": "https://finnhub.io/api/news?id=9d4ec59f6037fefdbdcd47a67f7600dc71ffa187ce9b258dd50d70a5e8a54a3c"
    }
  },
  {
    "ts": null,
    "headline": "Roche, Zealand sign deal: What it means for weight loss drug space",
    "summary": "Roche (ROG.SW) and Zealand Pharma (ZEAL.CO) stocks are in focus after the company announced an agreement to make amylin, an obesity drug, in a deal valued at $5.3 billion. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination Co-Hosts Julie Hyman and Josh Lipton to examine what the deal means for the pair of pharmaceutical companies and competitors like Eli Lilly (LLY) and Novo Nordisk (NVO). To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=f4a3b102142b36e27741b33f9ca4f26a5b985f6d88b256a6bed94ed4aeb3dba3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741809792,
      "headline": "Roche, Zealand sign deal: What it means for weight loss drug space",
      "id": 133184277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche (ROG.SW) and Zealand Pharma (ZEAL.CO) stocks are in focus after the company announced an agreement to make amylin, an obesity drug, in a deal valued at $5.3 billion. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination Co-Hosts Julie Hyman and Josh Lipton to examine what the deal means for the pair of pharmaceutical companies and competitors like Eli Lilly (LLY) and Novo Nordisk (NVO). To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=f4a3b102142b36e27741b33f9ca4f26a5b985f6d88b256a6bed94ed4aeb3dba3"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds?",
    "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town […]",
    "url": "https://finnhub.io/api/news?id=96c48fc5a3a99e5cfe6794ec33f20ae48ae575926964a8dead9639d33c26f5f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741803925,
      "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds?",
      "id": 133184279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town […]",
      "url": "https://finnhub.io/api/news?id=96c48fc5a3a99e5cfe6794ec33f20ae48ae575926964a8dead9639d33c26f5f0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Falling. Competition Is a Killer.",
    "summary": "Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=eb7bd3d62860d21b04cc822bd5b0942feaae2c3e6f932d000ba662f04880b544",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741803780,
      "headline": "Novo Nordisk Is Falling. Competition Is a Killer.",
      "id": 133184280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=eb7bd3d62860d21b04cc822bd5b0942feaae2c3e6f932d000ba662f04880b544"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns",
    "summary": "Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor confidence amid high risks.",
    "url": "https://finnhub.io/api/news?id=1b1678ebb3e62561104b9d812b15cfe72f5be371f6a3d0e1d12ec95dba4059de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741801773,
      "headline": "Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns",
      "id": 133159073,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/868454326/image_868454326.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor confidence amid high risks.",
      "url": "https://finnhub.io/api/news?id=1b1678ebb3e62561104b9d812b15cfe72f5be371f6a3d0e1d12ec95dba4059de"
    }
  },
  {
    "ts": null,
    "headline": "Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped",
    "summary": "Ignore the noise in GLP-1 stocks. Find the best value instead.",
    "url": "https://finnhub.io/api/news?id=76aa57814a2888dad90f20ae05d95061a58d63e2b6a41768b6ceb165d2d76708",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741795706,
      "headline": "Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped",
      "id": 133184282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Ignore the noise in GLP-1 stocks. Find the best value instead.",
      "url": "https://finnhub.io/api/news?id=76aa57814a2888dad90f20ae05d95061a58d63e2b6a41768b6ceb165d2d76708"
    }
  },
  {
    "ts": null,
    "headline": "Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%",
    "summary": "Roche inked a new deal in the obesity space, giving Novo Nordisk more competition in its own backyard.",
    "url": "https://finnhub.io/api/news?id=373621ca998c4ab5bd2833ce670a4183edd9d4024f9f62e3f025d34d62b4c96e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741795343,
      "headline": "Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%",
      "id": 133184283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche inked a new deal in the obesity space, giving Novo Nordisk more competition in its own backyard.",
      "url": "https://finnhub.io/api/news?id=373621ca998c4ab5bd2833ce670a4183edd9d4024f9f62e3f025d34d62b4c96e"
    }
  },
  {
    "ts": null,
    "headline": "Trump, Irish leader meet amid differences on Gaza war, trade",
    "summary": "U.S. President DonaldTrump met Irish Prime Minister Micheál Martin on Wednesday forwide-ranging talks that reflected differences over trade and theconflict in Gaza, although both leaders pledged...",
    "url": "https://finnhub.io/api/news?id=e50b938845233faff429f15af0aad0a716fa16fcd5a328ab7b4629c986de7a00",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741793425,
      "headline": "Trump, Irish leader meet amid differences on Gaza war, trade",
      "id": 133157140,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "U.S. President DonaldTrump met Irish Prime Minister Micheál Martin on Wednesday forwide-ranging talks that reflected differences over trade and theconflict in Gaza, although both leaders pledged...",
      "url": "https://finnhub.io/api/news?id=e50b938845233faff429f15af0aad0a716fa16fcd5a328ab7b4629c986de7a00"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Falling. Compeitition Is a Killer.",
    "summary": "Novo Nordisk Is Falling. Compeitition Is a Killer.",
    "url": "https://finnhub.io/api/news?id=f6ae87cbfdbdbc7a3e71e9fb11e94af185abaa621304ebbdac3068b9658332ae",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741789380,
      "headline": "Novo Nordisk Is Falling. Compeitition Is a Killer.",
      "id": 133157992,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk Is Falling. Compeitition Is a Killer.",
      "url": "https://finnhub.io/api/news?id=f6ae87cbfdbdbc7a3e71e9fb11e94af185abaa621304ebbdac3068b9658332ae"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Summit Fund Q4 2024 Commentary",
    "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
    "url": "https://finnhub.io/api/news?id=b6b7a9b04968ef2dc0344a2d4b9eee78d705f6cf8640e8b584642a4d569b9f25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741777200,
      "headline": "Invesco Summit Fund Q4 2024 Commentary",
      "id": 133149564,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149067144/image_2149067144.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
      "url": "https://finnhub.io/api/news?id=b6b7a9b04968ef2dc0344a2d4b9eee78d705f6cf8640e8b584642a4d569b9f25"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.",
    "summary": "Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.",
    "url": "https://finnhub.io/api/news?id=e1a2683e657119a65249fdaa230a4d765bd4bc09af39d924778f0e0b03d33af9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741775220,
      "headline": "Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.",
      "id": 133149992,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.",
      "url": "https://finnhub.io/api/news?id=e1a2683e657119a65249fdaa230a4d765bd4bc09af39d924778f0e0b03d33af9"
    }
  },
  {
    "ts": null,
    "headline": "Roche And Zealand Team Up To Develop Petrelintide",
    "summary": "Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.",
    "url": "https://finnhub.io/api/news?id=9c35ac5df6f9c210266e0bbc151356a22548e090e3c2cae765ee2ad6ed64d512",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741774517,
      "headline": "Roche And Zealand Team Up To Develop Petrelintide",
      "id": 133149287,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/644162813/image_644162813.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.",
      "url": "https://finnhub.io/api/news?id=9c35ac5df6f9c210266e0bbc151356a22548e090e3c2cae765ee2ad6ed64d512"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q4 2024 Review",
    "summary": "Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500Â® index.",
    "url": "https://finnhub.io/api/news?id=0d949fbfb9bc6d781dd942fc4d702b6a460558e2a5372e95abd05eb5e16657ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741773660,
      "headline": "Fidelity Select Health Care Portfolio Q4 2024 Review",
      "id": 133149109,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500Â® index.",
      "url": "https://finnhub.io/api/news?id=0d949fbfb9bc6d781dd942fc4d702b6a460558e2a5372e95abd05eb5e16657ae"
    }
  },
  {
    "ts": null,
    "headline": "Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.",
    "summary": "Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.",
    "url": "https://finnhub.io/api/news?id=d83d2a03fd9f71add4251f2541def761af6f5855d5031b681df6b31eec496679",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741767600,
      "headline": "Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.",
      "id": 133149993,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.",
      "url": "https://finnhub.io/api/news?id=d83d2a03fd9f71add4251f2541def761af6f5855d5031b681df6b31eec496679"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Rising Dividends Fund Q4 2024 Commentary",
    "summary": "Underperformance was driven by stock selection in the consumer discretionary, real estate and communication services sectors.",
    "url": "https://finnhub.io/api/news?id=741076e495eb879ea24e6e15d6c01f8f13a418ba63d2377a771e5c87420cc4f5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741767000,
      "headline": "Invesco Rising Dividends Fund Q4 2024 Commentary",
      "id": 133148473,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316707586/image_1316707586.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Underperformance was driven by stock selection in the consumer discretionary, real estate and communication services sectors.",
      "url": "https://finnhub.io/api/news?id=741076e495eb879ea24e6e15d6c01f8f13a418ba63d2377a771e5c87420cc4f5"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Equally-Weighted S&P 500 Fund Q4 2024 Commentary",
    "summary": "The fundâs underweights and stock selection in the information technology and consumer discretionary sectors had the largest negative effect on relative return.",
    "url": "https://finnhub.io/api/news?id=3f8c9049129dd4e0fabaf884d4ee29f1ae1565ad8e75e8b8da45e02a1dbfef92",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741765200,
      "headline": "Invesco Equally-Weighted S&P 500 Fund Q4 2024 Commentary",
      "id": 133148257,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1936201908/image_1936201908.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The fundâs underweights and stock selection in the information technology and consumer discretionary sectors had the largest negative effect on relative return.",
      "url": "https://finnhub.io/api/news?id=3f8c9049129dd4e0fabaf884d4ee29f1ae1565ad8e75e8b8da45e02a1dbfef92"
    }
  },
  {
    "ts": null,
    "headline": "US Senator Warren demands Medicare nominee Dr. Oz sever industry ties",
    "summary": "President DonaldTrump's nominee to lead the agency overseeing Medicare shoulddivest financial ties to healthcare and pharmaceutical companiesthat could benefit from his policy decisions, Democratic...",
    "url": "https://finnhub.io/api/news?id=3fd23d9de3d07dc6c3347c7eadee0dcd62f2074ad6ba92f4c63e94fc3ebdb6bc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741762800,
      "headline": "US Senator Warren demands Medicare nominee Dr. Oz sever industry ties",
      "id": 133147955,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "President DonaldTrump's nominee to lead the agency overseeing Medicare shoulddivest financial ties to healthcare and pharmaceutical companiesthat could benefit from his policy decisions, Democratic...",
      "url": "https://finnhub.io/api/news?id=3fd23d9de3d07dc6c3347c7eadee0dcd62f2074ad6ba92f4c63e94fc3ebdb6bc"
    }
  }
]